Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Merck
Mallinckrodt
Baxter
Medtronic

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR FONDAPARINUX SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Fondaparinux Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00038961 ↗ A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Completed Sanofi Phase 3 2001-11-01 This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC).
NCT00038961 ↗ A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Completed GlaxoSmithKline Phase 3 2001-11-01 This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression (IPC).
NCT00060554 ↗ A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) Withdrawn Schering-Plough Phase 2 2003-04-01 The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.
NCT00256100 ↗ Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure. Terminated Melbourne Health N/A 2004-06-01 The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new drug to prevent blood clotting in the continuous dialysis machine used in intensive care patients who have kidney failure.
NCT00320398 ↗ Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium) Completed GlaxoSmithKline Phase 3 2006-01-30 This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
NCT00320424 ↗ Hip Fracture Study of GSK576428 (Fondaparinux Sodium) Completed GlaxoSmithKline Phase 3 2006-02-16 This study is requested by PMDA to confirm the efficacy and the safety for HFS.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fondaparinux Sodium

Condition Name

Condition Name for Fondaparinux Sodium
Intervention Trials
Thrombosis, Venous 4
Venous Thromboembolism 4
Thromboembolism 3
Venous Thrombosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fondaparinux Sodium
Intervention Trials
Thrombosis 10
Thromboembolism 10
Venous Thrombosis 8
Venous Thromboembolism 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fondaparinux Sodium

Trials by Country

Trials by Country for Fondaparinux Sodium
Location Trials
United States 19
Germany 10
Italy 9
Canada 5
France 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fondaparinux Sodium
Location Trials
Michigan 2
California 2
Pennsylvania 2
Texas 2
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fondaparinux Sodium

Clinical Trial Phase

Clinical Trial Phase for Fondaparinux Sodium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fondaparinux Sodium
Clinical Trial Phase Trials
Completed 17
Terminated 2
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fondaparinux Sodium

Sponsor Name

Sponsor Name for Fondaparinux Sodium
Sponsor Trials
GlaxoSmithKline 18
University of Alabama at Birmingham 1
New York University School of Medicine 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fondaparinux Sodium
Sponsor Trials
Industry 21
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.